BR112022020042A2 - Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal - Google Patents

Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal

Info

Publication number
BR112022020042A2
BR112022020042A2 BR112022020042A BR112022020042A BR112022020042A2 BR 112022020042 A2 BR112022020042 A2 BR 112022020042A2 BR 112022020042 A BR112022020042 A BR 112022020042A BR 112022020042 A BR112022020042 A BR 112022020042A BR 112022020042 A2 BR112022020042 A2 BR 112022020042A2
Authority
BR
Brazil
Prior art keywords
hyperinflamation
stem cells
treat
mesenchymal
line precursor
Prior art date
Application number
BR112022020042A
Other languages
English (en)
Inventor
Itescu Silviu
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901052A external-priority patent/AU2020901052A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of BR112022020042A2 publication Critical patent/BR112022020042A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

MÉTODO PARA TRATAR HIPERINFLAMAÇÃO COM O USO DE CÉLULAS-TRONCO OU PRECURSORAS DE LINHAGEM MESENQUIMAL. A presente descrição se refere ao método de tratamento ou prevenção de hiperinflamação em um indivíduo em necessidade do mesmo, sendo que o método compreende administrar ao indivíduo uma composição que compreende células-tronco ou precursoras de linhagem mesenquimal (MLPSCs).
BR112022020042A 2020-04-03 2021-04-01 Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal BR112022020042A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
AU2020901052A AU2020901052A0 (en) 2020-04-03 Method for treating hyperinflammation which comprise administering mesenchymal lineage precursor or stem cells
AU2020901124A AU2020901124A0 (en) 2020-04-08 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902312A AU2020902312A0 (en) 2020-07-06 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902425A AU2020902425A0 (en) 2020-07-14 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020903041A AU2020903041A0 (en) 2020-08-25 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020903694A AU2020903694A0 (en) 2020-10-12 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020904312A AU2020904312A0 (en) 2020-11-23 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
PCT/EP2021/058683 WO2021198454A1 (en) 2020-04-03 2021-04-01 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells

Publications (1)

Publication Number Publication Date
BR112022020042A2 true BR112022020042A2 (pt) 2022-11-22

Family

ID=77927537

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020042A BR112022020042A2 (pt) 2020-04-03 2021-04-01 Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal

Country Status (9)

Country Link
US (1) US20230165904A1 (pt)
EP (1) EP4125957A1 (pt)
JP (1) JP2023520233A (pt)
KR (1) KR20220164741A (pt)
CN (1) CN115361959A (pt)
AU (1) AU2021245369A1 (pt)
BR (1) BR112022020042A2 (pt)
CA (1) CA3173216A1 (pt)
WO (1) WO2021198454A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230310507A1 (en) * 2020-07-20 2023-10-05 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions
CN112826833A (zh) * 2020-07-30 2021-05-25 中国人民解放军总医院第五医学中心 间充质干细胞在制备新冠肺炎引起的肺损伤修复药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
PT3027738T (pt) * 2013-08-01 2022-05-11 Swedish Stromabio Ab Mscs no tratamento de doenças pulmonares inflamatórias

Also Published As

Publication number Publication date
EP4125957A1 (en) 2023-02-08
WO2021198454A1 (en) 2021-10-07
KR20220164741A (ko) 2022-12-13
JP2023520233A (ja) 2023-05-16
US20230165904A1 (en) 2023-06-01
CA3173216A1 (en) 2021-10-07
AU2021245369A1 (en) 2022-11-03
CN115361959A (zh) 2022-11-18

Similar Documents

Publication Publication Date Title
BR112022020042A2 (pt) Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal
BR112018015097A2 (pt) composição e reatores
CR20190252A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
AR081450A1 (es) Tratamiento de sarcoidosis usando celulas madre de placenta
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
CO2022000481A2 (es) Inhibidores de enzimas
BR112022001054A2 (pt) Inibidores enzimáticos
MX2022000812A (es) Metodos de tratamiento de hiperplasia suprarrenal congenita.
BR112014016950A2 (pt) métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina
CO2022013055A2 (es) Tafoxiparina para el tratamiento de la preeclampsia
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112023018654A2 (pt) Compostos antibacterianos
BR112022001390A2 (pt) Inibidores de enzima
BR112023018655A2 (pt) Compostos antibacterianos
BR112022017557A2 (pt) Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal
BR112022009607A2 (pt) Inibidores de akt para melhorar a persistência de células t quimericas
BR112022018022A2 (pt) Método para tratar doença inflamatória intestinal ii
CO2023009893A2 (es) Métodos de tratamiento con moduladores del receptor de esfingosina-1-fosfato (s1p)
BR112022016448A2 (pt) Método para tratamento de doença do enxerto contra hospedeiro crônica
BR112021020525A2 (pt) Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação
BR112023021840A2 (pt) Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-tronco
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
CL2021001172A1 (es) Uso de tivozanib para tratar sujetos con cáncer refractario.
BR112014027646A2 (pt) método para tratar um indivíduo quanto a um distúrbio proliferativo celular, e método para prevenir ou inibir a perda induzida por uv da atividade de udp-glucuronosiltransferase (ugt) em um indivíduo